Dermatology

From viral hype to '100% results' claims, dermatologists outline five subtle yet crucial red flags that often mislead shoppers into buying products that overpromise and underdeliver

Tight synthetics, sweat and chemicals in gymwear can trigger textile dermatitis, a skin allergy more common than most people realise, warn dermatologists

Constant nail polish use may hide early signs of anaemia, diabetes or even cancer

Sun Pharma plans to leverage its global presence to accelerate patient access to this crucial treatment

Glenmark Pharmaceuticals and Ireland-based Cosmo Pharmaceuticals NV have received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a product for the treatment of acne vulgaris in the United Kingdom. In a joint statement, the companies said they have received approval for Winlevi, a topical treatment for acne vulgaris in patients aged 12 years and older. As part of the agreement inked in September 2023, Glenmark in-licensed the product from Cosmo Pharmaceuticals for distribution in Europe and South Africa. "Our partnership with Cosmo Pharmaceuticals plays an important role in enabling us to expand our dermatology portfolio, and we are proud to offer this new treatment to market that can improve the quality of life for those living with acne," Glenmark Pharmaceuticals President & Business Head - Europe and Emerging Markets Christoph Stoller said. Cosmo CEO Giovanni Di Napoli said the milestone underscores the company's commitment, alongside ...

.

The increasing incidence of skin diseases and the growing awareness about these conditions among the Indian populace have been pivotal in driving the dermatology market's expansion

The deal would enable Eris' entry into the Rs 3k cr injectables market, and it would become one of major players in the insulins segment with the acquisition of Biocon Biologic's Basalog and Insugen

Biocon had earlier sold its dermatology and nephrology branded formulation businesses to Eris for Rs 350 crore in November last year

The prevalence of atopic dermatitis in India has risen over the past three decades, with approximately 5.9 per cent of adults affected, of which 4.4 per cent suffer from a severe form of the disease

According to the firm's first-ever earnings update since its stock market debut earlier this month, consolidated revenue from operations grew 21 per cent Y-o-Y to Rs 496.1 crore

The business includes over 20 mother brands with revenue of Rs 90 crore in FY23 and the current run-rate is around Rs 100 crore

While Itani did not specify a timeline, he indicated that other brands from the division might also be introduced in India in the future

Sun Pharma is looking to fully acquire its Israel-based unit Taro Pharmaceutical Industries in order to integrate the dermatology business with itself and keep it profitable amid increasing competition in the segment, according to Managing Director Dilip Shanghvi. The Mumbai-based drug major has proposed to fully acquire Taro through a reverse triangular merger. The company has issued a letter to the Taro board with a proposal containing a non-binding indication of interest to acquire all of the outstanding ordinary shares for a purchase price of USD 38 per ordinary share in cash. Sun Pharma currently owns around 78 per cent stake in Taro. "My own assessment is that the dermatology business, which is the primary focus for Taro, is a business under constant, increasing competition pressure," Shanghvi said in an analyst call. He further said: "And as a stand-alone company, it will be very difficult for Taro as an independent company to continue to operate that business profitably. S

USFDA put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events

In January Eris had bought some derma brands from Glenmark Pharma as well

Eris and Dr. Reddy's did not immediately respond to Reuters' requests seeking the names of the dermatology brands

Sales trajectory in domestic formulations and resolution of regulatory issues are other triggers

According to reports, Torrent Pharmaceuticals is set to sign a deal to acquire Curatio Healthcare, a maker of skincare products, for Rs 2100 crore.

With a revenue base of Rs 195 crore in FY22, Oaknet brings a portfolio of leading brands in dermatology and women's health to the Eris stable.